| Peritoneal adipocytes and their role in inflammation during peritoneal dialysis. | |
| | |
| Jump to Full Text | |
MedLine Citation:
|
PMID: 20454534 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Adipose tissue is a major site of chronic inflammation associated with peritoneal dialysis (PD) frequently complicating peritonitis. Adiposity-associated inflammation plays a significant contributory role in the development of chronic inflammation in patients undergoing maintenance PD. However, the molecular and cellular mechanisms of this link remain uncertain. Adipose tissue synthesizes different adipokines and cytokines that orchestrate and regulate inflammation, insulin action, and glucose metabolism locally and systemically. In return, inflammation retards adipocyte differentiation and further exacerbates adipose dysfunction and inflammation. An understanding of the inflammatory roles played by adipose tissue during PD and the healing mechanism of injured mesothelium will help to devise new therapeutic approach to slow the progression of peritoneal damage during peritoneal dialysis. This article reviews the roles of peritoneal adipose tissue in chronic peritoneal inflammation under PD and in serosal repair during PD. |
| | |
Authors:
|
Kar Neng Lai; Joseph C K Leung |
Related Documents
:
|
8801524 - Modulation of murine peritoneal macrophage functions by gastrin. 468374 - Interaction of chlamydia psittaci reticulate bodies with mouse peritoneal macrophages. 2155864 - Effect of patulin on microbicidal activity of mouse peritoneal macrophages. 1518954 - Milky spots in the mouse omentum may play an important role in the origin of peritoneal... 19477034 - Macrophage activation by gastric fluid suggests mmp involvement in aspiration-induced l... 16897814 - Rapid cd40-mediated rescue from cd95-induced apoptosis requires tnfr-associated factor-... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2010-05-05 |
Journal Detail:
|
Title: Mediators of inflammation Volume: 2010 ISSN: 1466-1861 ISO Abbreviation: Mediators Inflamm. Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-05-10 Completed Date: 2010-08-10 Revised Date: 2010-09-28 |
Medline Journal Info:
|
Nlm Unique ID: 9209001 Medline TA: Mediators Inflamm Country: United States |
Other Details:
|
Languages: eng Pagination: 495416 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Queen Mary Hospital, University of Hong Kong, 102 Pokfulam Road, Hong Kong. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adipocytes
/
cytology*,
physiology Adipokines / physiology Adipose Tissue / physiology Antigens, CD / analysis Endothelial Cells / cytology, physiology Humans Inflammation / etiology, physiopathology* Leptin / physiology Peritoneal Dialysis / adverse effects* Peritonitis / physiopathology Polymerase Chain Reaction RNA, Messenger / genetics Regeneration Stem Cells / cytology, physiology |
| Chemical | |
Reg. No./Substance:
|
0/Adipokines; 0/Antigens, CD; 0/Leptin; 0/RNA, Messenger |
| Comments/Corrections | |
| Full Text | |
|
Journal Information Journal ID (nlm-ta): Mediators Inflamm Journal ID (publisher-id): MI ISSN: 0962-9351 ISSN: 1466-1861 Publisher: Hindawi Publishing Corporation |
Article Information Download PDF ![]() Copyright ? 2010 K. N. Lai and J. C. K. Leung. open-access: Received Day: 10 Month: 11 Year: 2009 Revision Received Day: 27 Month: 1 Year: 2010 Accepted Day: 17 Month: 2 Year: 2010 Print publication date: Year: 2010 Electronic publication date: Day: 5 Month: 5 Year: 2010 Volume: 2010E-location ID: 495416 ID: 2864891 PubMed Id: 20454534 DOI: 10.1155/2010/495416 |
| Peritoneal Adipocytes and Their Role in Inflammation during Peritoneal Dialysis | |
| Kar Neng LaiI1* | |
| Joseph C. K. LeungI1 | |
| Department of Medicine, Queen Mary Hospital, University of Hong Kong, 102 Pokfulam Road, Hong Kong |
|
| Correspondence: *Kar Neng Lai: knlai@hku.hk [other] Academic Editor: Giamila Fantuzzi |
|
Continuous ambulatory peritoneal dialysis (CAPD) has emerged as a major treatment modality in renal replacement program worldwide. It has distinct advantages over hemodialysis with a lower cost and simplicity of the technique. The ability to maintain the functional integrity of the peritoneal membrane allowing effective removal of fluid and metabolic waste is essential for the success of the treatment. Unfortunately, the peritoneal membrane frequently exhibits structurally changes following long-term dialysis due to the exposure of unphysiologic peritoneal dialysis fluid (PDF) with low pH and high glucose [1]. PDF also contains toxic substances including glucose degradation products (GDP) generated during the sterilization process and advanced glycation end products (AGE) produced from Amadori reaction between sugar and protein during long-term peritoneal dialysis (PD) [2]. These compounds cause irreversible damage to the peritoneal tissue leading to ultrafiltration failure and decline in dialysis efficacy [3, 4]. Previous studies have reported the detrimental effects of PDF on peritoneal cells including human peritoneal mesothelial cells (HPMC) [5?7] and endothelial cells [8, 9]. While adipose tissue is ubiquitously present in peritoneal tissue, information for the characteristics and pathophysiology of adipocytes following long-term exposure to PDF in maintenance CAPD remains scarce. Only until recently, adipocytes are considered as passive tissue for the storage of energy in the form of fat. However, there are now compelling evidences suggesting that adipocytes exert important metabolic and proinflammatory effects on peripheral tissue [10?12]. Furthermore, peritoneal adipocytes affect HPMC through the release of adipokines and, hence, alter the peritoneal physiology during PD [13, 14].
The parietal and visceral peritoneal surfaces are covered by a monolayer of mesothelium composed of mesothelial cells. Beneath the mesothelial cells are the basement membrane and submesothelial layer that contains collagen, fibroblasts, adipose tissue, blood vessels, and lymphatics [15]. Adipose tissue is abundant in omental or mesenteric peritoneum but less so in parietal, intestinal, and diaphragmatic peritoneum. Contrary to the prevailing view that adipose tissue functions only as an energy storage depot, compelling evidence reveals that adipocytes can mediate various physiological processes through secretion of an array of mediators and adipokines that include leptin, adiponectin, resistin, tumor necrosis factor-? (TNF-?), interleukin (IL)-6, transforming growth factor-? (TGF-?), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and other growth factors [16]. Moreover, adipocytes express receptors for leptin, insulin growth factor-1 (IGF-1), TNF-?, IL-6, TGF-? and may form a network of local autocrine, paracrine, and endocrine signals [17]. All of these adipokines exert important endocrine functions in chronic kidney diseases and may also contribute to systemic inflammation in these patients. This is of special significance in patients undergoing CAPD as the initiation of treatment is often associated with an increase in fat mass that could be associated with a polymorphism in uncoupling protein 2 which affects the energy metabolism in addition to glucose absorption from the PDF [18]. In contrast to findings in the general population, a number of studies have suggested that a higher body mass index (BMI) is associated with a better outcome in patients with kidney diseases [19]. Critical analysis reveals that the protective effect from a high BMI only applies to patients with a normal or high muscle mass [20]. A recent study indicates that an increased fat mass in PD, like in other patient groups, may indeed have adverse metabolic consequences with increased systemic inflammation and worst survival [21]. Interestingly, there is a difference in the release of growth factors between visceral and subcutaneous adipose tissue [22]. The omental adipose tissue, most affected by PD, releases IL-6 two to three folds higher than the subcutaneous fat tissue [23]. The visceral (truncal) fat mass correlates significantly with circulating IL-6 levels but not for nontruncal fat mass [24].
Ultrastructural study reveals that a portion of omental adipocytes protrude from the mesothelial surface, thus may come into direct contact with dialysate [15]. In addition, dialysate may also reach the parietal adipose tissue when the mesothelial monolayer is damaged. It is therefore logical to postulate that with repeated exposure to PDF and the continuous change in peritoneal physiology during CAPD, peritoneal adipocytes will inevitably be ?activated?. Although much work has focused on peritoneal mesothelial cells, scant attention has been paid to the role of peritoneal adipocytes during CAPD.
The stromal vascular fraction (SVF) is a heterogeneous cell population derived from the adipose tissue including omentum [25?27]. SVF is reported to be composed of endothelial cells identified as CD34+/CD31+ cells, infiltrating/resident macrophages defined as CD14+/CD31+ cells, and a population characterized as CD34+/CD31? cells. The CD34+/CD31? subset is a unique cell fraction capable of differentiating into adipocytes and is restricted to cells that do not express the mesenchymal stem cell marker CD105 [28]. It has been suggested that the adipocyte progenitor cells, that is, the preadipocytes, are included in the CD34+/CD31? cell fraction. This unique population is distinct from the multipotent adipose tissue-derived mesenchymal stem cells, which can be differentiated in vitro into other cell types including adipocytes [27], chondrocytes [29], osteoblasts [30, 31], and cardiomyocytes [32, 33]. The cellular number of SVF varies among individuals and so far there is no data studying whether PD alters the number of SVF in different adipose depots. Apart from the SVF, milky spots of the omentum also harbor stem cells [34], which proliferate to form the resident macrophage during peritoneal inflammation [35]. It remains unknown whether stem cells from milky spots have the same identity as stem cells in SVF with adipogenic potential. Milky spots are very small omental tissues in contact with peritoneal membrane, consisting of macrophages, lymphocytes, and plasma cells supported by blood and lymphatic vessels. Milky spots play a role in peritoneal infection and abdominal tumors [36, 37]. PD also activates the milky spots resulting in an increase in number and size during inflammatory process and PD [37, 38]. Milky spots transform into a lymph node-like structure where lymphocytes constitute the main cellular component after an episode of peritonitis [34].
Adipose tissues express and secrete a variety of cytokines and adipokines, which act locally as autocrine/paracrine mediators or systemically as endocrine factors (Table 1). Patients on PD have increased fat mass due to glucose absorption from the PDF. Increase in adiposity has been associated with sub-clinical inflammation with elevated adipokines synthesis. Among these adipokines, leptin is of particular interest as this peptide hormone is most abundant adipokine produced by adipocytes and is cleared principally by the kidney. The serum leptin concentration is increased in patients with chronic renal failure or undergoing dialysis [39, 40] and the serum leptin increases by 189% within a month after the initiation of PD treatment [41]. Leptin is also elevated during acute infection, in response to proinflammatory cytokines including IL-1 and TNF-? [39]. In the kidney, leptin stimulates cell proliferation and synthesis of collagen IV and TGF-? in glomerular endothelial cells. In glomerular mesangial cells, leptin increases the glucose transport, up-regulates the expression of the TGF-? type II receptor and the synthesis of collagen I through phosphatidylinositol-3-kinase related pathway [39]. Available data suggests that leptin triggers a paracrine interaction between glomerular endothelial and mesangial cells through the increased synthesis of TGF-? in glomerular endothelial cells and up-regulated TGF-? receptor expression in mesangial cells. It remains unclear whether such paracrine interaction operates between peritoneal adipocytes and HPMC. To the best of our knowledge, there is only one previous study on the effect of PDF on adipocytes that demonstrates increased leptin synthesis in a murine adipocyte cell line (3T3-L1) by glucose-containing PDF [42]. It is likely that pro-inflammatory mediators released by HPMC upon exposure to PDF could induce functional alteration of adjacent adipocytes. The likely candidates are IL-1 and TNF-?, TGF-?, VEGF, and IL-6. Indeed, a recent in vitro study has shown that IL-6 modulates leptin production and lipid metabolism in human adipose tissue [43]. Using cultured HPMC and SVF, we have shown that high glucose content in dialysate fluid is one of the major culprits that causes structural and functional abnormalities in peritoneal cells during CAPD [13, 44, 45]. Glucose significantly increases the protein synthesis of leptin by adipocytes in a dose-dependent manner and up-regulates the expression of leptin receptor, Ob-Rb, in HPMC [13]. The increased leptin production by adipocytes and enhanced Ob-Rb expression in HPMC following exposure to glucose suggest the existence of a cross-talk mechanism between adipocytes and mesothelial cells that may be relevant in peritoneal membrane dysfunction developed during peritoneal dialysis. HPMC cultured with conventional PDF induce higher expression of VEGF than that experiments with low-GDP-content PDF. In parallel, GDPs increase the gene and/or protein expression of VEGF in HPMC [46]. GDPs also decrease the expression of proteins associated with the tight junction, zonula occludens protein 1 (ZO-1), in HPMC [44]. Exogenous VEGF down-regulates the expression of ZO-1 while neutralizing anti-VEGF antibody reverses the effect of GDPs on ZO-1 expression in HPMC. These findings suggest that the action of GDPs on ZO-1 expression is mediated through VEGF.
A longitudinal study conducted in patients treated for PD-related peritonitis revealed elevation of serum leptin levels during acute peritonitis. The rise was contributed to anorexia in the earlier stage. In contrast, the serum adiponectin levels fell showing an inverse correlation between these two adipokines during acute peritonitis. Furthermore, the protracted course of inflammation even after bacterial cure of peritonitis was likely to cause the loss of lean body mass and to increase mortality [47].
Patients on maintenance PD have increased intraperitoneal levels of hyaluronan and cytokines including IL-1?, IL-6, and TGF-? [48, 49]. Chronic inflammation remains an important cause of morbidity in patients with end-stage renal failure. The main causes for inflammation in CAPD are PD-related peritonitis and exit site infection [50]. Patients on PD with peritonitis may experience prolonged inflammation even when clinical evaluation suggests resolution of PD-related peritonitis [51]. The highly sensitive C-reactive protein (hs-CRP) remains significantly higher than baseline even by day 42 after an episode of peritonitis [47]. There was persistent release of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in the peritoneal dialysate effluent (PDE) collected following an acute episode of CAPD-related peritonitis. NGAL synthesis is specifically induced in HPMC by IL-1? during peritonitis [52]. Interestingly, NGAL is also produced by adipocytes [53]. NGAL markedly affects the secretion of leptin and adiponectin by adipocytes, and acts as a negative regulator of inflammatory activity and inflammation-mediated adipocyte dysfunction. Incubation of HPMC with recombinant NGAL reverses the up-regulation of Snail and vimentin induced by TGF-?. Our data suggest that NGAL exerts a protective effect by modulating the epithelial-to-mesenchymal transition activated by peritonitis [52].
It has been shown that daily instillation of PDF for 5 weeks in rats leads to an increased number of omental mast cells and milky spots as well as damage to the mesothelial cell layer covering the peritoneum membrane [54]. Most interestingly, electron microscopy reveals that the severely damaged mesothelial cells are able to regenerate a good monolayer upon three months' rest of the peritoneum. The exact mechanism regulating this reversibility is not completely understood. Adipose tissues-derived SVF contains pluripotent mesenchymal stem cells that can regenerate damaged tissue [55]. An abundance of progenitor cells is also found in omentum [56]. Introduction of a foreign body into the peritoneal cavity further enhances the healing capability of the omentum by causing it to expand, surround the foreign body, and transform itself from mostly fatty tissue [56]. This transformed tissue (the activated omentum) contains abundant progenitor cells positive for CXCR-4 or Wilm's tumor-1 (WT-1), and is also rich in growth and angiogenic factors [56]. Activated omentum also facilitates liver regeneration following traumatic injury [57]. SVF cultured from omentum expresses pluripotent markers, produces high amounts of VEGF, and engrafts to injured sites [58]. These observations support a regenerative potential of mesothelium although the underlying mechanism remains undefined. The relative contribution of mesothelial cells, SVF or adipocytes in the adipose tissue and the relevant mechanism involved in the healing process of mesothelium after CAPD have not been well characterized.
During peritoneal dialysis, the undesirable microenvironment, chronic inflammation, and previous peritonitis all impose stress, causing damage to the peritoneal membrane. Remesothelialization or healing is possible if the peritoneum is allowed to rest [54]. Regeneration or healing of the mesothelium does not occur solely by centripetal migration of cells from the wound edge. It has been proposed that pluripotent cells beneath the mesothelium migrate towards the surface and differentiate into mature mesothelial cells [79?81]. Others suggest that the new mesothelium originates from a free-floating mesothelial cell or progenitors in the serosal fluid [82]. Different origins of cells in the regenerating mesothelium have been proposed and these include subserosal mesenchymal precursors, bone marrow-derived precursors, free-floating macrophages, and free-floating mesothelial cells. The exact identity of this cell population responsible for mesothelial repair remains uncertain.
Normal stem cells, mobilized from the bone marrow or resident in damaged tissue, play a pivotal role in tissue regeneration or healing after injury [83]. The ?-chemokine stromal-derived factor-1 (SDF-1) and its unique G-protein-coupled chemokine receptor (CXCR4) constitute the SDF-1/CXCR4 axis that regulates the trafficking of stem cells during the repair of damaged tissues. SDF-1 is involved in the regulation of CXCR4+ progenitor cell trafficking [84?86]. Proper functioning of the SDF-1/CXCR4 axis plays a pivotal role in the healing and regenerative processes of damaged tissue [87], and this may be relevant to the repair of peritoneal membrane after CAPD. Accumulation of these progenitor cells in peritoneal tissues is affected by a cascade of inflammatory mediators produced by peritoneal cells (including macrophages, mesothelial cells, endothelial cells, and adipocytes) following long-term exposure to PDF during peritoneal dialysis. Unpublished data from our laboratory and from the literature [88, 89] demonstrate that SDF-1, CXCR4, as well as the endogenous aminopeptidase dipeptidyl peptidase IV (DPPIV or CD26 that controls the degradative pathway of the SDF-1) are expressed by HPMC (Figures 1(a) to 1(d), unpublished data). Notably, peritoneal permeability in CAPD patients with frequent peritonitis deteriorates with parallel increased expression of TGF-? in dialysate [90]. The SDF-1 expression is up-regulated in damaged tissue following TGF-? treatment leading to an increased migratory potential of CXCR4 bearing cells (including HPMC and progenitor cells from the bone marrow or adipose tissue) to the SDF-1-positive niche [89]. Other cytokines including HGF and VEGF may also participate in the up-regulation of SDF-1 synthesis in injured tissue. Up-regulation of the SDF-1 expression implicates the reepithelialization of denuded basement membrane at the site of peritoneal injury. This hypothesis is supported by the observation of a time- and dose-dependent reduction of DPPIV and E-cadherin expression in HPMC following TGF-?-induced morphological change. Following the inhibition of DPPIV, degradation of CXCR4 is retarded and hence significantly enhances the migratory potential of CXCR4 positive HPMC towards the SDF-1 gradient in the injured tissue. Apart from TGF-?, HGF also affects the SDF-1/CXCR4 axis. HGF increases the CXCR4 expression and SDF-1 production in glioma and facilitates their invasion [91, 92]. HGF released during peritonitis also alters mesothelial cell phenotype and function [93]. We observe a dose-dependent up-regulation of CXCR4 expression in HPMC by HGF (Figures 1(e) and 1(f), unpublished data). The dialysate level of HGF remains persistently elevated even 28 days after an episode of peritonitis (Figure 1(g)). The pleiotropic HGF may initially affect the mesothelial healing by promoting mesothelial cell growth, but can also contribute to peritoneal fibrosis by stimulating cell detachment with mesothelial denudation and collagen synthesis [93, 94]. The pathophysiological impact of prolonged release of these pro-inflammatory mediators on the SDF-1/CXCR4 axis and the mesothelial healing remains to be examined. Figure 2 is a schematic outlining the potential role of peritoneal adipokines and their interplay with the SDF-1/CXCR4 axis in regulating the regeneration process of the mesothelium in CAPD.
Long-term peritoneal dialysis is often associated with structural alterations of the peritoneal membrane that are closely related to chronic local as well as systemic inflammatory responses. It is evident that peritoneal mesothelial cells, fibroblasts, and macrophages exert their effects on peritoneal membrane during PD. Increasing evidences reveal that peritoneal adipose tissue also plays an important role in the structural and functional alterations during PD. In particular, adipocytes release secretory adipokines and cytokines that play modulating roles in the inflammatory cascade and healing response of the mesothelium in PD. In the present review, we summarized the relevance of adipose tissue associated adipokines and cytokines in PD, with focuses on recent data related to the leptin synthesis by peritoneal adipocytes and the associated cellular crosstalk with mesothelial cells. The possible involvement of the SDF-1/CXCR4 axis and adipose tissue-derived mediators in the regeneration process of the injured mesothelium after PD was also discussed. In order to better preserve the integrity of the peritoneal membrane, which facilitates long-term CAPD, novel studies designed to elucidate the detailed interaction between different peritoneal cellular components with the adipocytes in the context of PD should be undertaken. Further studies on the identity of peritoneal progenitor cells and the precise role of the SDF-1/CXCR4 axis in maintaining the peritoneal membrane function for peritoneal dialysis are warranted.
The study was supported by the UGC-Matching Grant Scheme and the GRF Incentive Award (HKU 767809M).
| AGE: | Advanced glycation end products |
| DPPIV or CD26: | Aminopeptidase dipeptidyl peptidase IV |
| BMI: | Body mass index |
| CAPD: | Continuous ambulatory peritoneal dialysis |
| GDP: | Glucose degradation products |
| CXCR4: | G-protein-coupled chemokine receptor |
| HGF: | Hepatocyte growth factor |
| hs-CRP: | Highly sensitive C-reactive protein |
| HPMC: | Human peritoneal mesothelial cells |
| IGF-1: | Insulin growth factor-1 |
| IL: | Interleukin |
| NGAL: | Neutrophil Gelatinase-Associated Lipocalin |
| PDE: | Peritoneal dialysate effluent |
| PD: | Peritoneal dialysis |
| Peritoneal dialysis fluid | |
| SDF-1: | Stromal derived factor-1 |
| SVF: | Stromal vascular fraction |
| TGF-?: | Transforming growth factor-? |
| TNF-?: | Tumor necrosis factor-? |
| VEGF: | Vascular endothelial growth factor |
| WT-1: | Wilm's tumor-1 |
| ZO-1: | Zonula occludens protein 1. |
References
| 1. | Di Paolo N,Sacchi G,De Mia M,et al. Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysisNephronYear: 19864432042113785484 |
| 2. | Lamb EJ,Cattell WR,Dawnay ABSJ. In vitro formation of advanced glycation end products in peritoneal dialysis fluidKidney InternationalYear: 1995476176817747643548 |
| 3. | De Vriese AS,Mortier S,Lameire NH. What happens to the peritoneal membrane in long-term peritoneal dialysis?Peritoneal Dialysis InternationalYear: 200121supplement 3S9S1811887871 |
| 4. | Inagi R,Miyata T,Yamamoto T,et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysisFEBS LettersYear: 1999463326026410606733 |
| 5. | Ito T,Yorioka N,Yamamotcv M,Kataoka K,Yamakido M. Effect of glucose on intercellular junctions of cultured human peritoneal mesothelial cellsJournal of the American Society of NephrologyYear: 200011111969197911053471 |
| 6. | Zareie M,Hekking LHP,Welten AGA,et al. Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivoNephrology Dialysis TransplantationYear: 2003181226292637 |
| 7. | Ha H,Yu MR,Choi HN,et al. Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferationPeritoneal Dialysis InternationalYear: 200120supplement 5S10S1811229606 |
| 8. | Ogata S,Naito T,Yorioka N,Kiribayashi K,Kuratsune M,Kohno N. Effect of lactate and bicarbonate on human peritoneal mesothelial cells, fibroblasts and vascular endothelial cells, and the role of basic fibroblast growth factorNephrology Dialysis TransplantationYear: 2004191128312837 |
| 9. | Hekking LHP,Zareie M,Driesprong BAJ,et al. Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate-buffered solutionJournal of the American Society of NephrologyYear: 200112122775278611729248 |
| 10. | Ahima RS,Osei S. Adipokines in obesityFrontiers of Hormone ResearchYear: 20073618219718230903 |
| 11. | Tilg H,Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunityNature Reviews ImmunologyYear: 2006610772783 |
| 12. | Sommer G,Kralisch S,Stangl V,et al. Secretory products from human adipocytes stimulate proinflammatory cytokine secretion from human endothelial cellsJournal of Cellular BiochemistryYear: 2009106472973719173302 |
| 13. | Leung JCK,Chan LYY,Tang SCW,Chu KM,Lai KN. Leptin induces TGF-? synthesis through functional leptin receptor expressed by human peritoneal mesothelial cellKidney InternationalYear: 200669112078208616641931 |
| 14. | Yang A-H,Huang S-W,Chen J-Y,Lin J-K,Chen C-Y. Leptin augments myofibroblastic conversion and fibrogenic activity of human peritoneal mesothelial cells: a functional implication for peritoneal fibrosisNephrology Dialysis TransplantationYear: 2007223756762 |
| 15. | Di Paolo N,Sacchi G. Atlas of peritoneal histologyPeritoneal Dialysis InternationalYear: 200020supplement 3S5S9610877488 |
| 16. | Friedman JM. Obesity in the new millenniumNatureYear: 2000404677863263410766249 |
| 17. | Myers MG Jr.. Leptin receptor signaling and the regulation of mammalian physiologyRecent Progress in Hormone ResearchYear: 20045928730414749507 |
| 18. | Nordfors L,Heimb?rger O,L?nnqvist F,et al. Fat tissue accumulation during peritoneal dialysis is associated with a polymorphism in uncoupling protein 2Kidney InternationalYear: 20005741713171910760107 |
| 19. | Friedman AN. Adiposity in dialysis: good or bad?Seminars in DialysisYear: 200619213614016551291 |
| 20. | Beddhu S,Pappas LM,Ramkumar N,Samore M. Effects of body size and body composition on survival in hemodialysis patientsJournal of the American Society of NephrologyYear: 20031492366237212937315 |
| 21. | de Ara?jo IC,Kamimura MA,Draibe SA,et al. Nutritional parameters and mortality in incident hemodialysis patientsJournal of Renal NutritionYear: 2006161273516414438 |
| 22. | Fain JN,Madan AK,Hiler ML,Cheema P,Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humansEndocrinologyYear: 200414552273228214726444 |
| 23. | Mohamed-Ali V,Goodrick S,Rawesh A,et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-?, in vivoJournal of Clinical Endocrinology and MetabolismYear: 19978212419642009398739 |
| 24. | Axelsson J,Qureshi AR,Suliman ME,et al. Truncal fat mass as a contributor to inflammation in end-stage renal diseaseAmerican Journal of Clinical NutritionYear: 20048051222122915531669 |
| 25. | Nakagami H,Morishita R,Maeda K,Kikuchi Y,Ogihara T,Kaneda Y. Adipose tissue-derived stromal cells as a novel option for regenerative cell therapyJournal of Atherosclerosis and ThrombosisYear: 2006132778116733294 |
| 26. | Zuk PA,Zhu M,Ashjian P,et al. Human adipose tissue is a source of multipotent stem cellsMolecular Biology of the CellYear: 200213124279429512475952 |
| 27. | Zuk PA,Zhu M,Mizuno H,et al. Multilineage cells from human adipose tissue: implications for cell-based therapiesTissue EngineeringYear: 2001721122811304456 |
| 28. | Sengen?s C,Lolm?de K,Zakaroff-Girard A,Busse R,Bouloumi? A. Preadipocytes in the human subcutaneous adipose tissue display distinct features from the adult mesenchymal and hematopoietic stem cellsJournal of Cellular PhysiologyYear: 2005205111412215880450 |
| 29. | Majumdar MK,Banks V,Peluso DP,Morris EA. Isolation, characterization, and chondrogenic potential of human bone marrow-derived multipotential stromal cellsJournal of Cellular PhysiologyYear: 200018519810610942523 |
| 30. | Halvorsen YC,Wilkison WO,Gimble JM. Adipose-derived stromal cells?their utility and petential in bone formationInternational Journal of ObesityYear: 200024supplement 4S41S4411126240 |
| 31. | Halvorsen Y-DC,Franklin D,Bond AL,et al. Extracellular matrix mineralization and osteoblast gene expression by human adipose tissue-derived stromal cellsTissue EngineeringYear: 20017672974111749730 |
| 32. | Planat-B?nard V,Menard C,Andr? M,et al. Spontaneous cardiomyocyte differentiation from adipose tissue stroma cellsCirculation ResearchYear: 200494222322914656930 |
| 33. | Rangappa S,Fen C,Lee EH,Bongso A,Wei ESK. Transformation of adult mesenchymal stem cells isolated from the fatty tissue into cardiomyocytesAnnals of Thoracic SurgeryYear: 200375377577912645692 |
| 34. | Sacchi G,Di Paolo N,Venezia F,Rossi A,Nicolai G,Garosi G. Possible role of milky spots in mesothelial transplantationInternational Journal of Artificial OrgansYear: 200730652052617628853 |
| 35. | Wijffels JFAM,Hendrickx RJBM,Steenbergen JJE,Eestermans IL,Beelen RHJ. Milky spots in the mouse omentum may play an important role in the origin of peritoneal macrophagesResearch in ImmunologyYear: 199214344014091518954 |
| 36. | Sorensen EW,Gerber SA,Sedlacek AL,Rybalko VY,Chan WM,Lord EM. Omental immune aggregates and tumor metastasis within the peritoneal cavityImmunologic ResearchYear: 2009452-3185194 |
| 37. | Shimotsuma M,Shirasu M,Hagiwara A,Takahashi T,Shields JW. Omental milky spots and the local immune responseThe LancetYear: 19923398803p. 1232 |
| 38. | Di Paolo N,Sacchi G,Garosi G,et al. Omental milky spots and peritoneal dialysis?review and personal experiencePeritoneal Dialysis InternationalYear: 2005251485715770926 |
| 39. | Wolf G,Chen S,Han DC,Ziyadeh FN. Leptin and renal diseaseAmerican Journal of Kidney DiseasesYear: 200239111111774095 |
| 40. | Fr?hbeck G,G?mez-Ambrosi J,Muruz?bal FJ,Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulationAmerican Journal of PhysiologyYear: 20012806E827E84711350765 |
| 41. | Kim DJ,Oh DJ,Kim B,et al. The effect of continuous ambulatory peritoneal dialysis on change in serum leptinPeritoneal Dialysis InternationalYear: 199919supplement 2S172S17510406513 |
| 42. | Teta D,Tedjani A,Burnier M,Bevington A,Brown J,Harris K. Glucose-containing peritoneal dialysis fluids regulate leptin secretion from 3T3-L1 adipocytesNephrology Dialysis TransplantationYear: 200520713291335 |
| 43. | Trujillo ME,Sullivan S,Harten I,Schneider SH,Greenberg AS,Fried SK. Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitroJournal of Clinical Endocrinology and MetabolismYear: 200489115577558215531514 |
| 44. | Leung JCK,Chan LY,Li FFK,et al. Glucose degradation products downregulate ZO-1 expression in human peritoneal mesothelial cells: the role of VEGFNephrology Dialysis TransplantationYear: 200520713361349 |
| 45. | Leung JCK,Chan LYY,Tam KY,et al. Regulation of CCN2/CTGF and related cytokines in cultured peritoneal cells under conditions simulating peritoneal dialysisNephrology Dialysis TransplantationYear: 2009242458469 |
| 46. | Lai KN,Wieslander A,Chan LY,Tsang AW,Leung JC. Differential expression of receptors for advanced glycation endproducts in human mesothelial cells treated with glucose degradation products (GDP), conventional PD fluids and PD fluids with low GDP levelNephrology Dialysis TransplantationYear: 200318S2p. 210 |
| 47. | Lam MF,Leung JCK,Lo WK,et al. Hyperleptinaemia and chronic inflammation after peritonitis predicts poor nutritional status and mortality in patients on peritoneal dialysisNephrology Dialysis TransplantationYear: 200722514451450 |
| 48. | Lai KN,Szeto CC,Lai KB,Lam CWK,Chan DTM,Leung JCK. Increased production of hyaluronan by peritoneal cells and its significance in patients on CAPDAmerican Journal of Kidney DiseasesYear: 199933231832410023645 |
| 49. | Lai KN,Lai KB,Szeto CC,Lam CWK,Leung JCK. Growth factors in continuous ambulatory peritoneal dialysis effluentAmerican Journal of NephrologyYear: 199919341642210393381 |
| 50. | Pecoits-Filho R,Stenvinkel P,Wang AY-M,Heimb?rger O,Lindholm B. Chronic inflammation in peritoneal dialysis: the search for the holy grail?Peritoneal Dialysis InternationalYear: 200424432733915335146 |
| 51. | Lai KN,Lai KB,Lam CWK,Chan TM,Li FK,Leung JCK. Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysisAmerican Journal of Kidney DiseasesYear: 200035464465210739785 |
| 52. | Leung JCK,Lam MF,Tang SCW,et al. Roles of neutrophil gelatinase-associated lipocalin in continuous ambulatory peritoneal dialysis-related peritonitisJournal of Clinical ImmunologyYear: 200929336537819148711 |
| 53. | Sommer G,Weise S,Kralisch S,et al. Lipocalin-2 is induced by interleukin-1 ? in murine adipocytes in vitroJournal of Cellular BiochemistryYear: 2009106110310819009554 |
| 54. | Zareie M,Keuning ED,ter Wee PM,Beelen RHJ,van den Born J. Peritoneal dialysis fluid-induced changes of the peritoneal membrane are reversible after peritoneal rest in ratsNephrology Dialysis TransplantationYear: 2005201189193 |
| 55. | Gimble JM,Katz AJ,Bunnell BA. Adipose-derived stem cells for regenerative medicineCirculation ResearchYear: 200710091249126017495232 |
| 56. | Litbarg NO,Gudehithlu KP,Sethupathi P,Arruda JAL,Dunea G,Singh AK. Activated omentum becomes rich in factors that promote healing and tissue regenerationCell and Tissue ResearchYear: 2007328348749717468892 |
| 57. | Singh AK,Pancholi N,Patel J,et al. Omentum facilitates liver regenerationWorld Journal of GastroenterologyYear: 20091591057106419266597 |
| 58. | Singh AK,Patel J,Litbarg NO,et al. Stromal cells cultured from omentum express pluripotent markers, produce high amounts of VEGF, and engraft to injured sitesCell and Tissue ResearchYear: 20083321818818196277 |
| 59. | Fontan MP,Rodriguez-Carmona A,Cordido F,Garcia-Buela J. Hyperleptinemia in uremic patients undergoing conservative management, peritoneal dialysis, and hemodialysis: a comparative analysisAmerican Journal of Kidney DiseasesYear: 199934582483110561137 |
| 60. | Fawcett RL,Waechter AS,Williams LB,et al. Tumor necrosis factor-? inhibits leptin production in subcutaneous and omental adipocytes from morbidly obese humansJournal of Clinical Endocrinology and MetabolismYear: 200085253053510690850 |
| 61. | Tsujimoto Y,Shoji T,Tabata T,et al. Leptin in peritoneal dialysate from continuous ambulatory peritoneal dialysis patientsAmerican Journal of Kidney DiseasesYear: 199934583283810561138 |
| 62. | Teta D,Maillard M,Halabi G,Burnier M. The leptin/adiponectin ratio: potential implications for peritoneal dialysisKidney International. SupplementYear: 2008108S112S11818379533 |
| 63. | Huang J-W,Yen C-J,Chiang H-W,Hung K-Y,Tsai T-J,Wu K-D. Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal functionAmerican Journal of Kidney DiseasesYear: 20044361047105515168385 |
| 64. | Yaturu S,Reddy RD,Rains J,Jain SK. Plasma and urine levels of resistin and adiponectin in chronic kidney diseaseCytokineYear: 20073711517383891 |
| 65. | Taskapan MC,Taskapan H,Sahin I,Keskin L,Atmaca H,Ozyalin F. Serum leptin, resistin, and lipid levels in patients with end stage renal failure with regard to dialysis modalityRenal FailureYear: 200729214715417365928 |
| 66. | Bokarewa M,Nagaev I,Dahlberg L,Smith U,Tarkowski A. Resistin, an adipokine with potent proinflammatory propertiesJournal of ImmunologyYear: 2005174957895795 |
| 67. | Erten Y,Ebin? FA,Ebin? H,et al. The relationship of visfatin levels to inflammatory cytokines and left ventricular hypertrophy in hemodialysis and continuous ambulatory peritoneal dialysis patientsRenal FailureYear: 200830661762318661412 |
| 68. | Ziegelmeier M,Bachmann A,Seeger J,et al. Serum levels of adipokine retinol-binding protein-4 in relation to renal functionDiabetes CareYear: 200730102588259217630267 |
| 69. | Fassinger N,Imam A,Klurfeld DM. Serum retinol, retinol-binding protein, and transthyretin in children receiving dialysisJournal of Renal NutritionYear: 2010201172219616454 |
| 70. | Rogachev B,Hausmann MJ,Yulzari R,et al. Effect of bicarbonate-based dialysis solutions on intracellular pH (pH(i)) and TNF? production by peritoneal macrophagesPeritoneal Dialysis InternationalYear: 19971765465539655153 |
| 71. | Daviaud D,Boucher J,Gesta S,et al. TNFalpha up-regulates apelin expression in human and mouse adipose tissueThe FASEB JournalYear: 20062091528153016723381 |
| 72. | Pecoits-Filho R,Ara?jo MRT,Lindholm B,et al. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rateNephrology Dialysis TransplantationYear: 200217814801486 |
| 73. | Witowski J,J?rres A,Coles GA,Williams JD,Topley N. Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 mRNAKidney InternationalYear: 1996504121212238887280 |
| 74. | Fasshauer M,Klein J,Kralisch S,et al. Monocyte chemoattractant protein 1 expression is stimulated by growth hormone and interleukin-6 in 3T3-L1 adipocytesBiochemical and Biophysical Research CommunicationsYear: 2004317259860415063799 |
| 75. | Kleinz MJ,Davenport AP. Emerging roles of apelin in biology and medicinePharmacology and TherapeuticsYear: 2005107219821115907343 |
| 76. | Gerhardt CC,Romero IA,Cancello R,Camoin L,Strosberg AD. Chemokines control fat accumulation and leptin secretion by cultured human adipocytesMolecular and Cellular EndocrinologyYear: 20011751-2819211325518 |
| 77. | Fain JN,Madan AK. Regulation of monocyte chemoattractant protein 1 (MCP-1) release by explants of human visceral adipose tissueInternational Journal of ObesityYear: 200529111299130715997242 |
| 78. | Sell H,Dietze-Schroeder D,Kaiser U,Eckel J. Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscleEndocrinologyYear: 200614752458246716439461 |
| 79. | Mutsaers SE. Mesothelial cells: their structure, function and role in serosal repairRespirologyYear: 20027317119112153683 |
| 80. | Mutsaers SE,Pr?le CM,Lansley SM,Herrick SE. The origin of regenerating mesothelium: a historical perspectiveInternational Journal of Artificial OrgansYear: 200730648449417628849 |
| 81. | Herrick SE,Mutsaers SE. Mesothelial progenitor cells and their potential in tissue engineeringInternational Journal of Biochemistry and Cell BiologyYear: 200436462164215010328 |
| 82. | Foley-Comer AJ,Herrick SE,Al-Mishlab T,Pr?le CM,Laurent GJ,Mutsaers SE. Evidence for incorporation of free-floating mesothelial cells as a mechanism of serosal healingJournal of Cell ScienceYear: 200211571383138911896186 |
| 83. | Wang Y,Deng Y,Zhou G-Q. SDF-1?/CXCR4-mediated migration of systemically transplanted bone marrow stromal cells towards ischemic brain lesion in a rat modelBrain ResearchYear: 2008119510411218206136 |
| 84. | Kucia M,Jankowski K,Reca R,et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesionJournal of Molecular HistologyYear: 200435323324515339043 |
| 85. | Wojakowski W,Tendera M,Micha?owska A,et al. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarctionCirculationYear: 2004110203213322015533859 |
| 86. | Kucia M,Ratajczak J,Ratajczak MZ. Bone marrow as a source of circulating CXCR4+ tissue-committed stem cellsBiology of the CellYear: 200597213314615656779 |
| 87. | Ratajczak MZ,Zuba-Surma E,Kucia M,Reca R,Wojakowski W,Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesisLeukemiaYear: 200620111915192416900209 |
| 88. | Foussat A,Balabanian K,Amara A,et al. Production of stromal cell-derived factor 1 by mesothelial cells and effects of this chemokine on peritoneal B lymphocytesEuropean Journal of ImmunologyYear: 200131235035911180098 |
| 89. | Kajiyama H,Shibata K,Ino K,Nawa A,Mizutani S,Kikkawa F. Possible involvement of SDF-1?/CXCR4-DPPIV axis in TGF-?1-induced enhancement of migratory potential in human peritoneal mesothelial cellsCell and Tissue ResearchYear: 2007330222122917846797 |
| 90. | Lin CY,Chen WP,Fu LW,Yang LY,Huang TP. Persistent transforming growth factor beta 1 expression may predict peritoneal fibrosis in CAPD patients with frequent peritonitis occurrenceAdvances in Peritoneal DialysisYear: 19971364719360653 |
| 91. | Hong X,Jiang F,Kalkanis SN,et al. SDF-1 and CXCR4 are up-regulated by VEGF and contribute to glioma cell invasionCancer LettersYear: 20062361394515967572 |
| 92. | Zagzag D,Lukyanov Y,Lan L,et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasionLaboratory InvestigationYear: 200686121221123217075581 |
| 93. | Rampino T,Cancarini G,Gregorini M,et al. Hepatocyte growth factor/scatter factor released during peritonitis is active on mesothelial cellsAmerican Journal of PathologyYear: 200115941275128511583955 |
| 94. | Warn R,Harvey P,Warn A,et al. HGF/SF induces mesothelial cell migration and proliferation by autocrine and paracrine pathwaysExperimental Cell ResearchYear: 2001267225826611426944 |
Article Categories:
|
|
Previous Document: Venous Doppler in the evaluation of fetal hydrops.
Next Document: Physiological and histopathological investigations on the effects of alpha-lipoic acid in rats expos...
